{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Any study drug-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Any study drug-related Serious TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Treatment emergent adverse events (TEAEs) were defined as AEs starting or worsening during the treatment period. The treatment period extended from the first date of study treatment in this study until the safety follow-up (30 days after the last administration of study treatment). TESAEs: Treatment emergent serious adverse events.","groups":[{"description":"Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study.\n\n8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.","id":"OG000","title":"Anetumab Ravtansine"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Approximately 3 years (from first study treatment until safety follow-up)","title":"Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEs","type":"PRIMARY","unitOfMeasure":"Participants"}